Johannes Bloehdorn

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial

Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig et al. · Journal of Clinical Oncology · 2018 · 313 citations · Full text

Medicine, Hematology, Pharmacology +16

Postibrutinib outcomes in patients with mantle cell lymphoma

Peter Martin, Kami J. Maddocks, John P. Leonard et al. · Blood · 2016 · 283 citations · Full text

Medicine, Hematology, Oncology +8

Cellular origin and pathophysiology of chronic lymphocytic leukemia

Marc Seifert, Ludger Sellmann, Johannes Bloehdorn et al. · The Journal of Experimental Medicine · 2012 · 279 citations · Full text

Life Sciences, Cell Biology, Hematology +14

Venetoclax resistance and acquired <i>BCL2</i> mutations in chronic lymphocytic leukemia

Eugen Tausch, William Close, Anna Dolnik et al. · Haematologica · 2019 · 203 citations · Full text

Medicine, Genetics, Oncology +11

Additional Genetic High-Risk Features Such As 11q Deletion, 17p Deletion, and <i>V3-21</i> Usage Characterize Discordance of ZAP-70 and <i>VH</i> Mutation Status in Chronic Lymphocytic Leukemia

Alexander Kröber, Johannes Bloehdorn, Sebastian Häfner et al. · Journal of Clinical Oncology · 2006 · 193 citations · Full text

Medicine, Hematology, Oncology +15